fedratinib + rifampin

**fedratinib + rifampin** is a combination of fedratinib, an oral small molecule inhibitor of Janus kinase 2 (JAK2), and rifampin, a strong CYP3A4 inducer and antibiotic. Fedratinib is primarily indicated for intermediate-2 or high-risk primary or secondary myelofibrosis. Rifampin is commonly used to treat tuberculosis and as a prophylactic against Neisseria meningitidis carriage. When administered together, rifampin substantially decreases fedratinib plasma concentrations (by approximately 81%), due to enhanced hepatic metabolism via CYP3A4 induction, effectively compromising fedratinib's therapeutic efficacy. No therapeutic indication exists for their combination; instead, this combination is studied primarily for drug-drug interaction assessment, and its use is contraindicated or avoided in clinical practice[1][3][4][5].

Brand names

InrebicRifadin

Other names

fedratinibrifampicin